Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCL

Gilles Salles • 28 Jun 2021
EHA 2021
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Tafasitamab

Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY, talks on the use of tafasitamab for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a monoclonal antibody therapy targeted against CD19 and is used in combination with lenalidomide. Prof. Salles comments on the possibility of curing patients with DLBCL using this therapeutic combination. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Gilles Salles

1:56
How to manage follicular lymphoma
Gilles Salles • 18 Apr 2016
2:37
'Chemo-free' in follicular lymphoma
Gilles Salles • 19 Apr 2016

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals